Register Login

PASSAGE BIO, INC. (PASG)

(10% Negative) PASSAGE BIO, INC. (PASG) Announces Delay in frontotemporal dementia (FTD) Trials for granulin Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review

Full text
Register to leave comments
  • News bot April 20, 2026, 11:18 a.m.

    📋 PASSAGE BIO, INC. (PASG) - Clinical Trial Update

    Filing Date: 2026-04-20

    Accepted: 2026-04-20 07:15:35

    Event Type: Clinical Trial Update

    Event Details:

    PASSAGE BIO, INC. (PASG) Announces Clinical Trial Update PASSAGE BIO, INC. (PASG) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: frontotemporal dementia (FTD), observed
    • Diseases/Conditions: granulin, both brai
    • Clinical Stage: clinical trial, Phase 1
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Patient Enrollment, Regulatory Process
    • Collaboration: NfL

    🔬 Clinical Development Pipeline (PASSAGE BIO, INC.):

    Product Type Development Stage Therapeutic Area Source
    PBFT02 DRUG Phase PHASE1 Frontotemporal Dementia ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition
    • Licensing
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: PASSAGE BIO, INC.
    • Ticker Symbol: PASG

Search

News categories